Effects of early factor XIII replacement in postpartum hae morrhage: study protocol for a multicentre, open-label, randomised, controlled, investigator-initiated trial
Introduction The primary objective of this trial is to evaluate the effect of replenishing coagulation factor XIII (FXIII) in women with postpartum haemorrhage (PPH) on measured blood loss (MBL). Based on earlier research, we hypothesise that the administration of FXIII leads to a significant reduct...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-05-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/15/5/e100262.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849313107953844224 |
|---|---|
| author | Torsten Hothorn Christian Haslinger Verena Bossung Stylianos Kalimeris Elisabetta Ranieri Nicole Ochsenbein-Koelble Wolfgang Korte |
| author_facet | Torsten Hothorn Christian Haslinger Verena Bossung Stylianos Kalimeris Elisabetta Ranieri Nicole Ochsenbein-Koelble Wolfgang Korte |
| author_sort | Torsten Hothorn |
| collection | DOAJ |
| description | Introduction The primary objective of this trial is to evaluate the effect of replenishing coagulation factor XIII (FXIII) in women with postpartum haemorrhage (PPH) on measured blood loss (MBL). Based on earlier research, we hypothesise that the administration of FXIII leads to a significant reduction in postpartum blood loss.Methods and analysis This is a randomised, controlled trial that will allocate eligible patients in the event of a PPH and after receiving tranexamic acid either to the treatment group, receiving FXIII, or to the control group (standard of care). The primary endpoint is the MBL within 24 hours using a standardised method. For the primary analysis, estimation of the OR under a proportional odds assumption is conducted simultaneously for all possible cut-off points. A corresponding estimate, along with a two-sided 95% CI and two-sided p value against the null hypothesis OR=1, is obtained from the Continuous Outcome Logistic Regression model. More than 7000 patients will be screened in order to include a total of 988 eligible patients into the trial. Secondary outcomes include the rate of adverse maternal outcomes related to PPH, the rate of women breastfeeding after PPH and the safety of the administration of FXIII in women with PPH. Dynamics of blood coagulation factors in women with PPH and their association with MBL will be assessed in specific centres. A preliminary overview on costs and potential savings through early treatment of PPH with FXIII is included in the analysis as well as a patient and public involvement report, asking for patients’ personal experience during PPH in the main study centre.Ethics and dissemination Ethics approval was granted by the central ethics committee (Kantonale Ethikkommission Zürich/Switzerland) on 16 June 2024, reference number: BASEC 2024-00374. Results will be disseminated via open-access publication in a relevant medical journal.Trial registration number ClinicalTrials.gov ID NCT06481995. |
| format | Article |
| id | doaj-art-179bddff3e8a4e699aece7e64931f647 |
| institution | Kabale University |
| issn | 2044-6055 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-179bddff3e8a4e699aece7e64931f6472025-08-20T03:52:52ZengBMJ Publishing GroupBMJ Open2044-60552025-05-0115510.1136/bmjopen-2025-100262Effects of early factor XIII replacement in postpartum hae morrhage: study protocol for a multicentre, open-label, randomised, controlled, investigator-initiated trialTorsten Hothorn0Christian Haslinger1Verena Bossung2Stylianos Kalimeris3Elisabetta Ranieri4Nicole Ochsenbein-Koelble5Wolfgang Korte6Institut für Epidemiologie, Biostatistik und Prävention, Universität Zürich, Zürich, SwitzerlandDepartment of Obstetrics, University Hospital Zurich, Zürich, ZH, SwitzerlandDepartment of Obstetrics, University Hospital Zurich, Zürich, ZH, SwitzerlandDepartment of Obstetrics, University Hospital Zurich, Zürich, ZH, SwitzerlandDepartment of Obstetrics, University Hospital Zurich, Zürich, ZH, SwitzerlandDepartment of Obstetrics, University Hospital Zurich, Zürich, ZH, SwitzerlandZentrum Für Labormedizin (ZLM), St. Gallen, SwitzerlandIntroduction The primary objective of this trial is to evaluate the effect of replenishing coagulation factor XIII (FXIII) in women with postpartum haemorrhage (PPH) on measured blood loss (MBL). Based on earlier research, we hypothesise that the administration of FXIII leads to a significant reduction in postpartum blood loss.Methods and analysis This is a randomised, controlled trial that will allocate eligible patients in the event of a PPH and after receiving tranexamic acid either to the treatment group, receiving FXIII, or to the control group (standard of care). The primary endpoint is the MBL within 24 hours using a standardised method. For the primary analysis, estimation of the OR under a proportional odds assumption is conducted simultaneously for all possible cut-off points. A corresponding estimate, along with a two-sided 95% CI and two-sided p value against the null hypothesis OR=1, is obtained from the Continuous Outcome Logistic Regression model. More than 7000 patients will be screened in order to include a total of 988 eligible patients into the trial. Secondary outcomes include the rate of adverse maternal outcomes related to PPH, the rate of women breastfeeding after PPH and the safety of the administration of FXIII in women with PPH. Dynamics of blood coagulation factors in women with PPH and their association with MBL will be assessed in specific centres. A preliminary overview on costs and potential savings through early treatment of PPH with FXIII is included in the analysis as well as a patient and public involvement report, asking for patients’ personal experience during PPH in the main study centre.Ethics and dissemination Ethics approval was granted by the central ethics committee (Kantonale Ethikkommission Zürich/Switzerland) on 16 June 2024, reference number: BASEC 2024-00374. Results will be disseminated via open-access publication in a relevant medical journal.Trial registration number ClinicalTrials.gov ID NCT06481995.https://bmjopen.bmj.com/content/15/5/e100262.full |
| spellingShingle | Torsten Hothorn Christian Haslinger Verena Bossung Stylianos Kalimeris Elisabetta Ranieri Nicole Ochsenbein-Koelble Wolfgang Korte Effects of early factor XIII replacement in postpartum hae morrhage: study protocol for a multicentre, open-label, randomised, controlled, investigator-initiated trial BMJ Open |
| title | Effects of early factor XIII replacement in postpartum hae morrhage: study protocol for a multicentre, open-label, randomised, controlled, investigator-initiated trial |
| title_full | Effects of early factor XIII replacement in postpartum hae morrhage: study protocol for a multicentre, open-label, randomised, controlled, investigator-initiated trial |
| title_fullStr | Effects of early factor XIII replacement in postpartum hae morrhage: study protocol for a multicentre, open-label, randomised, controlled, investigator-initiated trial |
| title_full_unstemmed | Effects of early factor XIII replacement in postpartum hae morrhage: study protocol for a multicentre, open-label, randomised, controlled, investigator-initiated trial |
| title_short | Effects of early factor XIII replacement in postpartum hae morrhage: study protocol for a multicentre, open-label, randomised, controlled, investigator-initiated trial |
| title_sort | effects of early factor xiii replacement in postpartum hae morrhage study protocol for a multicentre open label randomised controlled investigator initiated trial |
| url | https://bmjopen.bmj.com/content/15/5/e100262.full |
| work_keys_str_mv | AT torstenhothorn effectsofearlyfactorxiiireplacementinpostpartumhaemorrhagestudyprotocolforamulticentreopenlabelrandomisedcontrolledinvestigatorinitiatedtrial AT christianhaslinger effectsofearlyfactorxiiireplacementinpostpartumhaemorrhagestudyprotocolforamulticentreopenlabelrandomisedcontrolledinvestigatorinitiatedtrial AT verenabossung effectsofearlyfactorxiiireplacementinpostpartumhaemorrhagestudyprotocolforamulticentreopenlabelrandomisedcontrolledinvestigatorinitiatedtrial AT stylianoskalimeris effectsofearlyfactorxiiireplacementinpostpartumhaemorrhagestudyprotocolforamulticentreopenlabelrandomisedcontrolledinvestigatorinitiatedtrial AT elisabettaranieri effectsofearlyfactorxiiireplacementinpostpartumhaemorrhagestudyprotocolforamulticentreopenlabelrandomisedcontrolledinvestigatorinitiatedtrial AT nicoleochsenbeinkoelble effectsofearlyfactorxiiireplacementinpostpartumhaemorrhagestudyprotocolforamulticentreopenlabelrandomisedcontrolledinvestigatorinitiatedtrial AT wolfgangkorte effectsofearlyfactorxiiireplacementinpostpartumhaemorrhagestudyprotocolforamulticentreopenlabelrandomisedcontrolledinvestigatorinitiatedtrial |